Type 2 diabetes and metabolic syndrome in youth

The single idea that organises everything in type 2 diabetes and metabolic syndrome in youth is insulin resistance with progressive beta-cell decline, layered on obesity and the metabolic cluster. Resist insulin and the beta cell drives out ever more of it, producing the acanthosis, ovarian hyperandrogenism, fatty liver, dyslipidaemia and hypertension that travel together. Exhaust the beta cell and glucose rises, because the compensatory output finally falls short. That is why one disease shows up as a whole cluster of metabolic risk, why acanthosis is the bedside clue, and why the complications arrive faster than in type 1 — the disease combines hyperglycaemia with every other cardiovascular risk factor at once. ^{[1] [5]}

This page covers the recognition, diagnosis and management of type 2 diabetes and metabolic syndrome in children and adolescents: the pathophysiology of insulin resistance and beta-cell failure, the acanthosis and metabolic cluster at the bedside, the diagnostic criteria with antibody and C-peptide confirmation, the exclusion of type 1 and monogenic diabetes, the stepwise ladder of lifestyle, metformin, insulin, GLP-1 receptor agonists and SGLT2 inhibitors, and the aggressive comorbidity and complication care that defines the disease as faster and more dangerous than its adult counterpart. It links to the dedicated leaves for type 1 diabetes, diabetic ketoacidosis, and monogenic diabetes rather than repeating their full pathways. ^[1]

Overview & Definition

Type 2 diabetes in youth is defined by insulin resistance combined with progressive beta-cell failure, set against obesity and genetic or ethnic susceptibility. The defining feature is not the absence of insulin but its loss of effect, followed by the exhaustion of the beta cells that try to compensate. Residual insulin usually prevents ketogenesis, which is why presentation is often insidious and picked up on screening rather than at a crisis. ^[1]

The metabolic syndrome is the constellation that type 2 diabetes belongs to. Central adiposity sits at its core, and it gathers dyslipidaemia, hypertension and raised fasting glucose around it, with insulin resistance as the shared mechanism. The IDF consensus defines it in adolescents as central adiposity with a waist circumference at or above the 90th percentile plus two or more of triglycerides at least 1.7 millimoles per litre, low HDL, blood pressure at least 130 over 85, and fasting glucose at least 5.6 millimoles per litre. ^{[6] [5]}

What sets youth-onset type 2 apart is its aggression. Beta-cell function is already roughly 50 to 80 percent reduced at diagnosis, and it declines about 15 to 20 percent per year — far faster than in adults. Half of adolescents fail metformin monotherapy within a few years, and complications appear early. The disease is therefore not a mild or stable version of adult diabetes but a faster, more dangerous variant that demands intensive treatment from the outset. ^{[10] [11]}

References12ShowHide

1. [1]Shah AS; Zeitler PS; Wong J; et al ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. Pediatr Diabetes, 2022.PMID 36161685
2. [2]Lawrence JM; Divers J; Isom S; et al Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. JAMA, 2021.PMID 34427600
3. [3]Wagenknecht LE; Lawrence JM; Isom S; et al Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002-18: results from the population-based SEARCH for Diabetes in Youth study. Lancet Diabetes Endocrinol, 2023.PMID 36868256
4. [4]Jensen ET; Dabelea D Type 2 Diabetes in Youth: New Lessons from the SEARCH Study. Curr Diab Rep, 2018.PMID 29737424
5. [5]Tropeano A; Corica D; Li Pomi A; et al The metabolic syndrome in pediatrics: do we have a reliable definition? A systematic review. Eur J Endocrinol, 2021.PMID 34061767
6. [6]Zimmet P; Alberti KG; Kaufman F; et al The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes, 2007.PMID 17850473
7. [7]Maguolo A; Maffeis C Acanthosis nigricans in childhood: A cutaneous marker that should not be underestimated, especially in obese children. Acta Paediatr, 2020.PMID 31560795
8. [8]Laffel LM; Danne T; Klingensmith GJ; et al Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a randomised trial. Lancet Diabetes Endocrinol, 2023.PMID 36738751
9. [9]Kim G; Divers J; Fino NF; et al Trends in prevalence of cardiovascular risk factors from 2002 to 2012 among youth early in the course of type 1 and type 2 diabetes. The SEARCH for Diabetes in Youth Study. Pediatr Diabetes, 2019.PMID 30903717
10. [10]Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med, 2012.PMID 22540912
11. [11]Dabelea D; Stafford JM; Mayer-Davis EJ; et al Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA, 2017.PMID 28245334
12. [12]Marcus MD; Wilfley DE; El Ghormli L; et al Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience. Pediatr Obes, 2017.PMID 27161901